Skip to main content
AmigoFish

The Fat-Cure Hype Faces COLLAPSE. Tesamorelin Peptide Has a Cancer Warning.

From The Infographics Show · · 16 min

The player loads from YouTube only when you click. It uses YouTube's privacy-enhanced mode.

If the video does not play, the owner may have turned off embedding. Watch it on YouTube instead.

Watch on YouTube

Not rated yet

Description

Tesamorelin is being promoted as a peptide that can target the dangerous visceral fat surrounding your organs, but how does it actually work?

Unlike traditional weight-loss drugs, Tesamorelin doesn’t directly suppress appetite or simply burn calories. It mimics Growth Hormone-Releasing Hormone, or GHRH, signaling the pituitary gland to increase the body’s own natural pulses of growth hormone. That matters because visceral fat appears particularly sensitive to growth hormone signaling. Tesamorelin was originally developed to treat HIV-associated lipodystrophy, a condition that can cause dangerous abdominal fat accumulation in people receiving antiretroviral therapy. In 2010, the FDA approved it under the brand name Egrifta. Clinical trials found that Tesamorelin reduced visceral abdominal fat by roughly 15–20% without necessarily producing dramatic changes on the scale. Research has also explored potential effects on liver fat, metabolic health, inflammation, and even cognitive function. But manipulating the growth hormone axis comes with real trade-offs. Side effects can include injection-site reactions, joint pain, fluid retention, numbness, changes in glucose tolerance, and increased IGF-1 levels that require monitoring. Brand-name treatment can also cost thousands of dollars per month. And once treatment stops, much of the visceral fat can return.

Tesamorelin may be one of the most clinically validated peptides available, but a smaller waistline can come with a much bigger commitment.

00:25 - How Tesamorelin Targets Visceral Fat 01:33 - The HIV Crisis That Led to Tesamorelin 02:36 - How Tesamorelin Activates Growth Hormone 05:02 - FDA Approval and the Rise of Egrifta 06:12 - What Clinical Trials Show About Visceral Fat Loss 08:59 - The Unexpected Effects on the Brain and Metabolism 11:50 - Side Effects, Glucose Risk and Cancer Concerns 14:14 - The High Cost, Gray Market and Rebound Problem

Narrated by: Josh Risser

🔔 Don't forget to SUBSCRIBE! 🔔

SUGGEST A TOPIC: https://bit.ly/suggest-an-infographics-video

💬 Come chat with me: https://discord.gg/theinfoshow

🔖 MY SOCIAL PAGES TikTok ► https://www.tiktok.com/@theinfographicsshow Facebook ► https://www.facebook.com/TheInfographicsShow

📝 SOURCES: https://pastebin.com/jFxesu5h

All videos are based on publicly available information unless otherwise noted.

Back to The Infographics Show · Report a problem